NCT00019669View on ClinicalTrials.gov

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

October 31, 1999

Study Completion Date

October 31, 2007

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

aldesleukin

BIOLOGICAL

fowlpox virus vaccine vector

BIOLOGICAL

gp100 antigen

Trial Locations (1)

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00019669 - Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma | Biotech Hunter | Biotech Hunter